Simple, Noninvasive Eye Test May Identify Risk for Stroke

Share this content:
Simple, Noninvasive Eye Test May Identify Risk for Stroke
Simple, Noninvasive Eye Test May Identify Risk for Stroke

(HealthDay News) – An eye test measuring ocular pulse amplitude (OPA) can be performed by ophthalmologists to detect severe carotid artery stenosis (CAS), a known risk factor for stroke, according to a study published in the June issue of Ophthalmology.

Pascal B. Knecht, MD, from the University Hospital of Zurich, and colleagues used dynamic contour tonometry to measure the OPA on both eyes of 42 men and 25 women (mean age, 67 years) and evaluate its accuracy as a screening test for CAS.

The researchers found that the means of the OPA values differed significantly in patients with no CAS (less than 50% blockage) compared to patients with severe stenosis (70% or greater blockage) (P=0.036). A multivariate analysis, using risk factors for CAS, including age, total cholesterol, low-density lipoprotein, and triglycerides, showed a statistically significant odds ratio for the ability of downstream OPA measurements to predict CAS of 70% or greater (odds ratio, 0.46; P=0.007).

"The results of the present study provide proof of principle that the OPA is reduced in patients with CAS and may be used as a noninvasive, inexpensive, readily available, and unconfounded screening parameter to detect CAS and possibly to reduce the incidence of stroke," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs